Reinier de Graaf Gasthuis

The trials here

What the 21 trials at this site are about, from their registry records.

Conditions

• Atrial fibrillation3 trials
• Colorectal cancer2 trials
• Gastric and oesophageal cancer2 trials
• Heart failure2 trials
• High blood pressure2 trials
• Obesity2 trials
• Acute myeloid leukaemia1 trial
• Atopic dermatitis (eczema)1 trial
• Chronic lymphocytic leukaemia1 trial
• Deep vein thrombosis and pulmonary embolism1 trial
• Diabetic foot ulcer1 trial
• Familial hypercholesterolaemia1 trial
• and 7 more

Phase

• Phase 38 trials
• Phase 23 trials
• Phase 41 trial

Status

• Completed9 trials
• Active, not recruiting6 trials
• Not yet recruiting3 trials
• Recruiting3 trials

Lead sponsor

• Corsano Health B.V.4 trials
• Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)3 trials
• Amgen2 trials
• Borstkanker Onderzoek Groep1 trial
• Dutch Society of Physicians for Pulmonology and Tuberculosis1 trial
• and 10 more

Running trials

• Recruiting

  Prospective Data Collection Initiative on Thoracic Malignancies

  NCT06996249· Dutch Society of Physicians for Pulmonology and Tuberculosis· Source

  Contact: F.T.A. van der Velde

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  NCT07037433· Phase 3· Amgen· Source

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  NCT07037459· Phase 3· Amgen· Source

• Not yet recruiting

  Multi-Centre Based Study Recognition of Atrial Fibrillation With the Corsano CardioWatch 287-2 System

  NCT06955273· Corsano Health B.V.· Source

  Contact: Eelko Ronner, MD, PhD

• Not yet recruiting

  FRAILTY Classification Algorithm for the Corsano CARDIOWATCH 287-2: a Development and Validation Study

  NCT06930833· Corsano Health B.V.· Source

  Contact: Eelko Ronner, MD, PhD

• Active, not recruiting

  The UPDATE Trial (Uvb Phototherapy in Dermatology for ATopic Eczema)

  NCT05704205· Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)· Source

• Recruiting

  Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2

  NCT04628026· Phase 3· University of Ulm· Source

• Active, not recruiting

  SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast)

  NCT05392608· Phase 2· Borstkanker Onderzoek Groep· Source

• Recruiting

  Circulating Tumor DNA Based Adjuvant Chemotherapy in Stage II Colon Cancer Patients: the MEDOCC-CrEATE Trial

  NCT06434896· UMC Utrecht· Source

  Contact: A.J. Verschoor

• Active, not recruiting

  Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer

  NCT03764553· Phase 2· Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)· Source

• Active, not recruiting

  Multicentric Randomised Trial for Resectable Gastric Cancer

  NCT02931890· Phase 2· The Netherlands Cancer Institute· Source

• Active, not recruiting

  A Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients

  NCT02301286· Phase 3· Leiden University· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute myeloid leukaemia1 recruiting
• Atrial fibrillation1 recruiting
• Colorectal cancer1 recruiting
• Heart failure1 recruiting
• Lung cancer1 recruiting
• Mesothelioma1 recruiting
• Myelodysplastic syndromes1 recruiting
• Obesity1 recruiting
• Thymoma and thymic carcinoma1 recruiting

Closed trials

• Completed

  Blood Pressure Treatment by the Corsano CardioWatch 287-2 Evaluation Study

  NCT06508619· Corsano Health B.V.· Source

• Completed

  REmote CArdiac MOnitoring by the Corsano CardioWatch 287-2 Evaluation Study

  NCT05899959· Corsano Health B.V.· Source

• Completed

  Personalised Assistive Devices Approach for Diabetic Foot Ulcer Prevention

  NCT05236660· Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)· Source

• Completed

  Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies

  NCT05142722· Phase 3· NewAmsterdam Pharma· Source

• Completed

  Digoxin Evaluation in Chronic Heart Failure: Investigational Study In Outpatients in the Netherlands

  NCT03783429· Phase 4· University Medical Center Groningen· Source

• Completed

  A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes

  NCT03914326· Phase 3· Novo Nordisk A/S· Source

• Completed

  Safety and Efficiency of the YEARS Algorithm Versus Computed Tomography Pulmonary Angiography Alone for Suspected Pulmonary Embolism in Patients With Malignancy

  NCT04657120· Leiden University Medical Center· Source

• Completed

  Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

  NCT02950051· Phase 3· German CLL Study Group· Source

• Completed

  R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL

  NCT01865110· Phase 3· The Lymphoma Academic Research Organisation· Source